Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when these cells are triggered with lipopolysaccharide and other agonists in culture. 40% inhibition occurs at the clinically achievable dose of the drug of 1 micrograms/ml. In contrast, the amo...

Descripción completa

Detalles Bibliográficos
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 1991
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118820/
https://www.ncbi.nlm.nih.gov/pubmed/1997652
_version_ 1782141115243167744
collection PubMed
description Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when these cells are triggered with lipopolysaccharide and other agonists in culture. 40% inhibition occurs at the clinically achievable dose of the drug of 1 micrograms/ml. In contrast, the amount of total protein and individual proteins labeled with [35S]methionine and expressed on SDS-PAGE are not influenced. The amounts of interleukin 1 beta (IL-1 beta), IL-6, and granulocyte/macrophage colony-stimulating factor produced by monocytes remain unaltered. The selectivity of this drug may be useful in determining the role of TNF-alpha in vivo and modulating its toxic effects in a clinical setting.
format Text
id pubmed-2118820
institution National Center for Biotechnology Information
language English
publishDate 1991
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21188202008-04-17 Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes J Exp Med Articles Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when these cells are triggered with lipopolysaccharide and other agonists in culture. 40% inhibition occurs at the clinically achievable dose of the drug of 1 micrograms/ml. In contrast, the amount of total protein and individual proteins labeled with [35S]methionine and expressed on SDS-PAGE are not influenced. The amounts of interleukin 1 beta (IL-1 beta), IL-6, and granulocyte/macrophage colony-stimulating factor produced by monocytes remain unaltered. The selectivity of this drug may be useful in determining the role of TNF-alpha in vivo and modulating its toxic effects in a clinical setting. The Rockefeller University Press 1991-03-01 /pmc/articles/PMC2118820/ /pubmed/1997652 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Articles
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
title Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
title_full Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
title_fullStr Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
title_full_unstemmed Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
title_short Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
title_sort thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118820/
https://www.ncbi.nlm.nih.gov/pubmed/1997652

Ejemplares similares